Oncolytic Viruses in the Treatment of Bladder Cancer
Bladder carcinoma is the second most common malignancy of the urinary tract. Up to 85% of patients with bladder cancer are diagnosed with a tumor that is limited to the bladder mucosa (Ta, T1, and CIS). These stages are commonly termed as non-muscle-invasive bladder cancer (NMIBC). Although the trea...
Saved in:
| Main Authors: | Kyle G. Potts, Mary M. Hitt, Ronald B. Moore |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2012/404581 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti‐tumor immunity with superior safety in bladder cancer models
by: Kyle G Potts, et al.
Published: (2017-03-01) -
Oncolytic Viruses
by: Nanhai G. Chen, et al.
Published: (2012-01-01) -
Improved oncolytic activity of a reovirus mutant that displays enhanced virus spread due to reduced cell attachment
by: Francisca Cristi, et al.
Published: (2024-06-01) -
Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer
by: Jin Guo, et al.
Published: (2025-03-01) -
Oncolytic virotherapy provides a potent therapy option for squamous bladder cancer
by: Julia Pannhausen, et al.
Published: (2025-04-01)